WO1996020690A2 - 3,3-(disubstituted)cyclohexan-1-ylidine acetate monomers and related compounds - Google Patents

Abstract

The present invention relates to novel 3,3-(disubstituted)cyclohexan-1-ylidine acetate monomers and related compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF).

Description

3,3-(Disubstituted)cyclohexan-l-ylidine Acetate Monomers and

Related Compounds

Field of Invention

The present invention relates to novel 3,3-(disubstituted)cyclohexan-l-ylidine acetate monomers and related compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF).

Background of the Invention

Bronchial asthma is a complex, multifactorial disease characterized by reversible narrowing of the airway and hyperreactivity of the respiratory tract to external stimuli.

Identification of novel therapeutic agents for asthma is made difficult by the fact that multiple mediators are responsible for the development of the disease. Thus, it seems unlikely that eliminating the effects of a single mediator will have a substantial effect on all three components of chronic asthma. An alternative to the "mediator approach" is to regulate the activity of the cells responsible for the pathophysiology of the disease.

One such way is by elevating levels of cAMP (adenosine cyclic 3\5'- monophosphate). Cyclic AMP has been shown to be a second messenger mediating the biologic responses to a wide range of hormones, neurotransmitters and drugs; [Krebs Endocrinology Proceedings of the 4th International Congress Excerpta Medica, 17-29, 1973]. When the appropriate agonist binds to specific cell surface receptors, adenylate cyclase is activated, which converts Mg⁺2-ATP to cAMP at an accelerated rate. Cyclic AMP modulates the activity of most, if not all, of the cells that contribute to the pathophysiology of extrinsic (allergic) asthma. As such, an elevation of cAMP would produce beneficial effects including: 1 ) airway smooth muscle relaxation, 2) inhibition of mast cell mediator release, 3) suppression of neutrophil degranulation, 4) inhibition of basophil degranulauon, and 5) inhibition of monocyte and macrophage activation. Hence, compounds that activate adenylate cyclase or inhibit phosphodiesterase should be effective in suppressing the inappropriate activation of airway smooth muscle and a wide variety of inflammatory cells. The principal cellular mechanism for the inactivation of cAMP is hydrolysis of the 3 - phosphodiester bond by one or more of a family of isozymes referred to as cyclic nucleoude phosphodiesterases (PDEs). It has now been shown that a distinct cyclic nucleotide phosphodiesterase

(PDE) isozyme, PDE IV, is responsible for cAMP breakdown in airway smooth muscle and inflammatory cells. [Torphy, "Phosphodiesterase Isozymes: Potential Targets for Novel Anti-asthmatic Agents" in New Drugs for Asthma, Barnes, ed. IBC Technical Services Ltd., 1989]. Research indicates that inhibition of this enzyme not only produces airway smooth muscle relaxation, but also suppresses degranulation of mast cells, basophils and neutrophils along with inhibiting the activation of monocytes and neutrophils. Moreover, the beneficial effects of PDE IV inhibitors are markedly potentiated when adenylate cyclase activity of target cells is elevated by appropriate hormones or autocoids, as would be the case in vivo. Thus PDE IV inhibitors would be effective in the asthmatic lung, where levels of prostaglan din E2 and prostacyclin (activators of adenylate cyclase) are elevated. Such compounds would offer a unique approach toward the pharmacotherapy of bronchial asthma and possess significant therapeutic advantages over agents currendy on the market.

The compounds of this invention also inhibit the production of Tumor Necrosis Factor (TNF), a serum glycoprotein. Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoaithritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption diseases, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to human acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis, in addition to a number of autoimmune diseases, such as multiple sclerosis, autoimmune diabetes and systemic lupus erythematosis.

AIDS results from the infection of T lymphocytes with Human Immunodeficiency Virus (HIV). At least three types or strains of HIV have been identified, i.e., HIV-1, HTV-2 and HIV-3. As a consequence of HIV infection, T-cell- mediated immunity is impaired and infected individuals manifest severe opportunistic infections and/or unusual neoplasms. HIV entry into the T lymphocyte requires T lymphocyte activation. Viruses such as HIV-1 or HIV-2 infect T lymphocytes after T cell activation and such virus protein expression and/or replication is mediated or maintained by such T cell activation. Once an activated T lymphocyte is infected with HIV, the T lymphocyte must continue to be maintained in an activated state to permit HIV gene expression and/or HTV replication.

Cytokines, specifically TNF, are implicated in activated T-cell-mediated HTV protein expression and/or virus replication by playing a role in maintaining T lymphocyte activation. Therefore, interference with cytokine activity such as by inhibition of cytokine production, notably TNF, in an HTV-infected individual aids in limiting the maintenance of T cell activation, thereby reducing the progression of HTV infectivity to previously uninfected cells which results in a slowing or elimination of the progression of immune dysfunction caused by HTV infection. Monocytes, macrophages, and related cells, such as kupffer and glial cells, have also been implicated in maintenance of the HTV infection. These cells, like T cells, are targets for viral replication and the level of viral replication is dependent upon the activation state of the cells. [See Rosenberg et al. , The Immunopathogenesis of HTV Infection, Advances in Immunology, Vol. 57, 1989]. Monokines, such as TNF, have been shown to activate HIV replication in monocytes and/or macrophages [See Poli et al, Proc. Nad. Acad. Sci., 87:782-784, 1990], therefore, inhibition of monokine production or activity aids in limiting HIV progression as stated above for T cells.

TNF has also been implicated in various roles with other viral infections, such as the cytomegalovirus (CMV), influenza virus, adenovirus, and the herpes virus for similar reasons as those noted.

TNF is also associated with yeast and fungal infections. Specifically Candida albicans has been shown to induce TNF production in vitro in human monocytes and natural killer cells. [See Rϋpi et al. Infection and Immunity, 58(9):2750-54, 1990; and Jafari et al, Journal of Infectious Diseases, 164:389-95, 1991. See also Wasan et al, Antimicrobial Agents and Chemotherapy, 35,(10):2046-48, 1991 ; and Luke et al, Journal of Infectious Diseases, 162:211-214,1990].

The ability to control the adverse effects of TNF is furthered by the use of the compounds which inhibit TNF in rria nmals who are in need of such use. There remains a need for compounds which are useful in treating TNF-mediated disease states which are exacerbated or caused by the excessive and/or unregulated production of TNF. Summary of the Invention

The novel c by formula (I):

wherein:

R₂ is -(CR4R5)nC(O)O(CR4R5)mR6, -(CR4R5)nC(O)NR4(CR4R5)m 6, -(CR4R5)_nO(CR4R5)_mR6, or -(C_-4R5)_rR6 wherein the alkyl moieties unsubstituted or substituted with one or more halogens; m is 0 to 2; n is 0 to 4; r is 0 to 6;

R4 and R5 are independently selected hydrogen or Ci-2 alkyl; R6 is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCi-3 alkyl, halo substituted aryloxyCi-3 alkyl, indanyl, indenyl, C7-11 polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3-6 cycloalkyl, or a C4_6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocyclic moiety is unsubstituted or substituted by 1 to 3 methyl groups, one ethyl group, or an hydroxyl group; provided that: a) when R6 is hydroxyl, then m is 2; or b) when R6 is hydroxyl, then r is 2 to 6; or c) when R6 is 2-tetrahydropyranyl, 2-tetr__ιydrothiopyranyl,

2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then m is 1 or 2; or d) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl,or 2-tetrahydrothienyl, then r is 1 to 6; e) when n is 1 and m is 0, then Rβ is other than H in -(CR4R5)nO(CR4R5)mR6;

X is YR2, fluorine, NR4R5, or formyl amine; Y is O or S(O)nϊ; m' is O, l, or 2; X2 is O or NR8; X3 is hydrogen or X;

X4 is H, R9, OR8, CN, C(O)Rg, C(O)ORs, C(O)NRgR8, or NRgRδ; R2 is independently selected from -CH3 or -CH2CH3 optionally substituted by 1 or more halogens; s is 0 to 4; W is alkyl of 2 to 6 carbons, alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms;

R₃ is COOR14, C(O)NR4Rl4 or R7;

Z is C(-CN)2, CR14CN, CRi4C(O)OR8, CRi4C(O)NR8Rl4, C(-CN)NO2, C(-CN)C(O)OR9, C(-CN)OC(O)R9, C(-CN)OR9, or C(-CN)C(O)NRsRl4; Y' is O or S;

R7 is -(CR4R5)qRl2 or Ci.g alkyl wherein the R12 or Ci.g alkyl group is unsubstituted or substituted one or more times by methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -F, -Br, -Cl, -NO2, -NR₁₀Rι _{l f} -C(O)Rδ, -CO2R8, -O(CH₂)_qR8, -CN, -C(O)NRi₀Rl l, -O(CH₂)_qC(O)NRi₀Rl l, -O(CH₂)_qC(O)R₉₎ -NRiθC(O)NRiθRn, -NRιoC(O)Rn, -NRioC(O)OR9, -NRιoC(O)Ri3, -C(NRiθ)NRlθRl -C(NCN)NRioRl l, -C(NCN)SR9, -NRioC(NCN)SR9 , -NRιoC(NCN)NRιoRl l, -NRιoS(O)₂R9, -S(O)_m__9, -NRioC(O)C(O)NRιoRl l, - NRi C(O)C(O)Rio, or R₁₃; q is O, 1, or 2;

Rl2 is i3, C3-C7 cycloalkyl, or an unsubstituted or substituted aryl or heteroaryl group selected from the group consisting of (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, (1- or 2-imidazolyl), pyrrolyl, piperazinyl, piperidinyl, morpholinyl, furanyl, (2- or 3-thienyl), quinolinyl, naphthyl, and phenyl; Rg is hydrogen or R9;

R9 is Cι_4 alkyl optionally substituted by one to three fluorines; RlO is ORδ or Rn;

Rj 1 is hydrogen, or C 1.4 alkyl unsubstituted or substituted by one to three fluorines; or when Rio and Ri 1 are as NRioRl 1 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and one or more additional heteroatoms selected from O, N, or S;

Rl3 is a substituted or unsubstituted heteroaryl group selected from the group consisting of oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, and thiadiazolyl, and where Rι₃ is substituted on R_J2 or Rι₃ the rings are connected through a carbon atom and each second R|₃ ring may be unsubstituted or substituted by one or two C _2 alkyl groups unsubstituted or substituted on the methyl with 1 to 3 fluoro atoms;

Rl4 is hydrogen or R7; or when R8 and R 14 are as NRδRl4 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and one or more additional heteroatoms selected from O, N, or S; provided that:

(f) R7 is not C _4 alkyl unsubstituted or substituted by one to three fluorines; or the pharmaceutically acceptable salts thereof. This invention also relates to the pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent. The invention also relates to a method of mediation or inhibition of the enzymatic activity (or catalytic activity) of PDE IV in mammals, including humans, which comprises administering to a mammal in need thereof an effective amount of a compound of Formula (I) as shown below.

The invention further provides a method for the treatment of allergic and inflammatory disease which comprises __iministering to a mammal, including humans, in need thereof, an effective amount of a compound of Formula (I). The invention also provides a method for the treatment of asthma which comprises axiministering to a mammal, including humans, in need thereof, an effective amount of a compound of Formula (I).

This invention also relates to a method of inhibiting TNF production in a mammal, including humans, which method comprises administering to a mammal in need of such treatment, an effective TNF inhibiting amount of a compound of Formula (I). This method may be used for the prophylactic treatment or prevention of certain TNF mediated disease states amenable thereto.

This invention also relates to a method of treating a human afflicted with a human immunodeficiency virus (HIV), which comprises axiministering to such human an effective TNF inhibiting amount of a compound of Formula (I).

Compounds of Formula (I) are also useful in the treatment of additional viral infections, where such viruses are sensitive to upregulation by TNF or will elicit TNF production in vivo. In addition, compounds of Formula (I) are also useful in treating yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production in vivo.

Detailed Description of the Invention

This invention also relates to a method of mediating or inhibiting the enzymatic activity (or catalytic activity) of PDE IV in a mammal in need thereof and to inhibiting the production of TNF in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I).

Phosphodiesterase IV inhibitors are useful in the treatment of a variety of allergic and ir_fl__τ_rnatory diseases including: asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome. In addition, PDE IV inhibitors are useful in the treatment of diabetes insipidus and central nervous system disorders such as depression and multi-infarct dementia.

The viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibitors of Formula (I). Such viruses include, but are not limited to HTV-1, HTV-2 and HTV-3, cytomegalovirus (CMV), influenza, adenovirus and the Herpes group of viruses, such as, but not limited to, Herpes zoster and Herpes simplex. This invention more specifically relates to a method of treating a m___ mal, afflicted with a hiiman immunodeficiency virus (HIV), which comprises administering to such ____mmal an effective TNF inhibiting amount of a compound of Formula (I). The compounds of this invention may also be used in association with the veterinary treatment of animals, other than in humans, in need of inhibition of TNF production. TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections. Examples of such viruses include, but are not limited to feline immunodeficiency virus (FIV) or other retroviral infection such as equine infectious anemia virus, caprine arthritis virus, visna virus, maedi virus and other lentiviruses. The compounds of this invention are also useful in treating yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production in vivo. A preferred disease state for treatment is fungal meningitis. Additionally, the compounds of Formula (I) may be -administered in conjunction with other drugs of choice for systemic yeast and fungal infections. Drugs of choice for fungal infections, include but are not limited to the class of compounds called the polymixins, such as Polymycin B, the class of compounds called the imidazoles, such as clotrimazole, econazole, miconazole, and ketoconazole; the class of compounds called the triazoles, such as fluconazole, and itranazole, and the class of compound called the Amphotericins, in particular Amphotericin B and liposomal Amphotericin B.

The compounds of Formula (I) may also be used for inhibiting and/or reducing the toxicity of an anti-fungal, anti-bacterial or anti-viral agent by administering an effective amount of a compound of Formula (I) to a mammal in need of such treatment. Preferably, a compound of Formula (I) is adirύnistered for inhibiting or reducing the toxicity of the Amphotericin class of compounds, in particular Amphotericin B.

Preferred compounds are as follows:

When Ri for the compounds of Formula (I) is an alkyl substituted by 1 or more halogens, the halogens are preferably fluorine and chlorine, more preferably a C i _4 alkyl substituted by 1 or more fluorines. The preferred halo-substituted alkyl chain length is one or two carbons, and most preferred are the moieties -CF3, -CH2F, - CHF2, -CF2CHF2, -CH2CF3, and -CH2CHF2. Preferred Ri substitutents for the compounds of Formula (I) are CH2-cyclopropyl, CH2-C5-6 cycloalkyl, C4.6 cycloalkyl with or without an hydroxyl group on the ring, C7- 11 polycycloalkyl, (3- or 4-cyclopentenyl), phenyl, tetrahydrofuran-3-yl, benzyl or Ci-2 alkyl unsubstituted or substituted by 1 or more fluorines, -(CH2)l-3C(O)O(CH2)0-2CH3, -(CH2)1-3O(CH2)0-2CH3, and -(CH2)2-4OH. When the Ri term is (CR4R5), the R4 and R5 terms are independently hydrogen or alkyl. This allows for branching of the individual methylene units as (CR4R5)n or (CR4R5)m; each repeating methylene unit is independent of the other, e.g., (CR4R5)n wherein n is 2 can be -CH2CH(-CH3)-, for instance. The individual hydrogen atoms of the repeating methylene unit or the branching hydrocarbon can unsubstituted or be substituted by fluorine independent of each other to yield, for instance, the preferred Ri substitutions, as noted above.

When Ri is a C7_ι 1 polycycloalkyl, examples are bicyclo[2.2.1]-heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, tricyclo[S.2.1.0²>⁶]decy__> etc. additional examples of which are described in Saccamano et al., WO 87/06576, published 5 November 1987, whose disclosure is incorporated herein by reference in its entirety.

Preferred Z terms are C(-CN)2, CRi4C(O)OR8, CRi4C(O)NR8Rl4, C(-CN)C(O)OR9, C(-CN)OC(O)R9, C(-CN)OR9, or C(-CN)C(O)NRδRl4;

Preferred X groups for Formula (I) are those wherein X is YR2 and Y is oxygen. The preferred X2 group for Formula (I) is that wherein X2 is oxygen. The preferred X3 group for Formula (I) is that wherein X3 is hydrogen. Preferred R2 groups, where applicable, is a Ci-2 alkyl unsubstituted or substituted by 1 or more halogens. The halogen atoms are preferably fluorine and chlorine, more preferably fluorine. More preferred R2 groups are those wherein R2 is methyl, or the fluoro- substituted alkyls, specifically a C 1-2 alkyl, such as a -CF3, -CHF2, or -CH2CHF2 moiety. Most preferred are the -CHF2 and -CH3 moieties. Preferred R3 moiety is R7.

Preferred R7 moieties include unsubstituted or substituted -(CH2)0-2(2-, 3- or 4-pyridyl), (CH2)l-2(2-imidazolyl), (CH2)2(4-morpholinyl), (CH2)2(4-piperazinyl), (CH2) 1 -2(2-thienyl), (CH2) 1 -2(4-thiazolyl), unsubstituted or substituted pyrimidinyl, and substituted or unsubstituted (CH2)0-2phenyl.

Preferred rings when Rio and Ri 1 in the moiety -NRioRl 1 together with the nitrogen to which they are attached form a 5 to 7 membered ring comprised of carbon or carbon and at least one heteroatom selected from O, N, or S include, but are not limited to 1 -imidazolyl, 2-(R8)- 1 -imidazolyl, 1 -pyrazolyl, 3-(R8)- 1 -pyrazolyl, 1 - triazolyl, 2-triazolyl, 5-(R8)-l-triazolyl, 5-(R8)-2-triazolyl, 5-(R8)-l-tetr___olyl, 5-(R8)-2-tetrazolyl, 1-tetrazolyl, 2-tetrazloyl, morpholinyl, piperazinyl, 4-(R8)-l- piperazinyl, or pyrrolyl ring.

Preferred rings when Rδ and R 14 in the moiety -NRsRl4 together with the nitrogen to which they are attached may form a 5 to 7 membered ring comprised of carbon or carbon and at least one heteroatom selected from O, N, or S include, but are not limited to 1 -imidazolyl, 1 -pyrazolyl, 1 -triazolyl, 2-triazolyl, 1-tetrazolyl, 2-tetrazolyl, morpholinyl, piperazinyl, and pyrrolyl. The respective rings may be additionally substituted, where applicable, on an available nitrogen or carbon by the moiety R7 as described herein for Formula (I). Illustrations of such carbon substitutions includes, but is not limited to, 2-(R7)-l -imidazolyl, 4-(R7)-l -imidazolyl, 5-(R7)- 1 -imidazolyl, 3-(R7)- 1 -pyrazolyl, 4-(R7)- 1 -pyrazolyl, 5-(R7)- 1 -pyrazolyl, 4-(R7)-2-triazolyl, 5-(R7)-2-triazolyl, 4-(R7)- 1 -triazolyl, 5-(R7)- 1 -triazolyl,

5-(R7)-l-tetrazolyl, and 5-(R7)-2-tetrazolyl. Applicable nitrogen substitution by R7 includes, but is not limited to, l-(R7)-2-tεtrazolyl, 2-(R7)-l-tetrazolyl, 4-(R7)-l- piperazinyl. Where applicable, the ring may be substituted one or more times by R7.

Preferred groups for NRδRl4 which contain a heterocyclic ring are 5-(Ri4)-l- tetrazolyl, 2-(R 14)- 1 -imidazolyl, 5-(Ri4)-2-tetrazolyl, or 4-(Rι 4)- 1 -piperazinyl.

Preferred rings for R13 include (2-, 4- or 5-imidazolyl), (3-, 4- or 5-pyrazolyl), (4- or 5-triazolyl[ 1,2,3]), (3- or 5-triazolyl[ 1,2,4]), (5-tetrazolyl), (2-, 4- or 5-oxazolyl), (3-, 4- or 5-isoxazolyl), (3- or 5-oxadiazolyl[ 1,2,4]), (2-oxadiazolyl[ 1,3,4]), (2-thiadiazolyl[ 1,3,4]), (2-, 4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl), (2-, 4-, or 5-thiazolidinyl), or (2-, 4-, or 5-iι_ύd__.olidinyl).

When the R7 group is unsubstituted or substituted by a heterocyclic ring such as imidazolyl, pyrazolyl, triazolyl, tetrazolyl, or thiazolyl, the heterocyclic ring itself may be unsubstituted or substituted by Rδ either on an available nitrogen or carbon atom, such as l-(Rδ)-2-imidazolyl, l-(R8)-4-imidazolyl, l-(R8)-5-imidazolyl, l-(R8)-3-pyrazolyl, l-(R8)-4-pyrazolyl, l-(R8)-5-pyrazolyl, l-(R8)-4-triazolyl, or l-(R8)-5-triazolyl. Where applicable, the ring may be substituted one or more times by

Rδ-

Preferred are those compounds of Formula (I) wherein R is -CH2- cyclopropyl, -CH2-C5-6 cycloalkyl, -C4.-6 cycloalkyl unsubstituted or substituted by OH, tetrahydrofuran-3-yl, (3- or 4-cyclopentenyl), benzyl or -Ci_2 alkyl unsubstituted or substituted by 1 or more fluorines, and -(CH2)2-4 OH; R2 is methyl or fluoro- substituted alkyl, W is ethynyl or 1,3-butadiynyl; R₃ is R₇ where R is an unsubstituted or substituted aryl or heteroaryl ring, X is YR2, and Z is CRi4C(O)ORδ-

Most preferred are those compounds wherein Ri is -CH2-cyclopropyl, cyclopentyl, 3-hydroxycyclopentyl, methyl or CF2H; X is YR2; Y is oxygen; X2 is oxygen; X3 is hydrogen; and R2 is CF2H or methyl, W is ethynyl or 1,3-butadiynyl, and R3 is a substituted or unsubstituted pyrimidinyl ring. Exemplified compounds are:

1 ,4-bis- { [3-(3-cyclopentyloxy-4-methoxyphenyl) cyclohexan- 1 -on]-3-yl } buta- 1,3-diyne,

1 ,4-bis- { ([3-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan- 1 - yUdine]malononitrile)-3-yl } buta- 1 ,3-diyne, and 1 ,4-bis- [ (methyl [3-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan- 1 - yUdine]acetate)-3-yl }buta- 1 ,3-diyne.

The term "C^ alkyl", "C alkyl", "C β alkyl" or "alkyl" groups as used herein is meant to include both straight or branched chain radicals of 1 to 10, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and the like.

"Alkenyl" means both straight or branched chain radicals of 1 to 6 carbon lengths, unless the chain length is limited thereto, including but not limited to vinyl, 1- propenyl, 2-propenyl, 2-propynyl, or 3-methyl-2-propenyl. The term "cycloalkyl" or "cycloalkyl alkyl" means groups of 3-7 carbon atoms, such as cyclopropyl, cyclopropylmethyl, cyclopentyl, or cyclohexyl.

"Aryl" or "aralkyl", unless specified otherwise, means an aromatic ring or ring system of 6-10 carbon atoms, such as phenyl, benzyl, phenethyl, or naphthyl. Preferably the aryl is monocyclic, i.e, phenyl. The alkyl chain is meant to include both straight or branched chain radicals of 1 to 4 carbon atoms.

"Heteroaryl" means an aromatic ring system containing one or more heteroatoms, such as imidazolyl, triazolyl, oxazolyl, pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, furanyl, or thienyl.

"Halo" means all halogens, i.e., chloro, fluoro, bromo, or iodo. "Inhibiting the production of IL- 1 " or "inhibiting the production of TNF" means: a) a decrease of excessive in vivo IL-1 or TNF levels, respectively, in a human to normal levels or below normal levels by inhibition of the in vivo release of IL-1 by all cells, including but not limited to monocytes or macrophages; b) a down regulation, at the translational or transcriptional level, of excessive in vivo IL-1 or TNF levels, respectively, in a human to normal levels or below normal levels; or c) a down regulation, by inhibition of the direct synthesis of IL-1 or TNF levels as a postranslational event. The phrase "TNF mediated disease or disease states" means any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another cytokine to be released, such as but not limited to IL-1 or IL-6. A disease state in which IL-1, for instance is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would therefore be considered a disease state mediated by TNF. As TNF-β (also known as lymphotoxin) has close structural homology with TNF-α (also known as cachectin), and since each induces similar biologic responses and binds to the same cellular receptor, both TNF-α and TNF-β are inhibited by the compounds of the present invention and thus are herein referred to collectively as "TNF" unless specifically delineated otherwise. Preferably

TNF-α is inhibited.

"Cytokine" means any secreted polypeptide that affects the functions of cells, and is a molecule which modulates interactions between cells in immune, inflammatory, or hematopoietic responses. A cytokine includes, but is not limited to, monokines and lymphokines regardless of which cells produce them.

The cytokine inhibited by the present invention for use in the treatment of a HTV- infected human must be a cytokine which is implicated in (a) the initiation and/or maintenance of T cell activation and/or activated T cell-mediated HTV gene expression and/or replication, and/or (b) any cytokine-mediated disease associated problem such as cachexia or muscle degeneration. Preferrably, his cytokine is TNF-α.

All of the compounds of Formula (I) are useful in the method of inhibiting the production of TNF, preferably by macrophages, monocytes or macrophages and monocytes, in a mammal, including humans, in need thereof. All of the compounds of Formula (I) are useful in the method of inhibiting or mediating the enzymatic or catalytic activity of PDE IV and in treatment of disease states mediated thereby. Pha_τnaceutically acceptable salts of the instant compounds, where they can be prepared, are also intended to be covered by this invention. These salts will be ones which are acceptable in their application to a pharmaceutical use. By that it is meant that the salt will retain the biological activity of the parent compound and the salt will not have untoward or deleterious effects in its application and use in treating diseases.

Pharmaceutically acceptable salts are prepared in a standard manner.

The parent compound, dissolved in a suitable solvent, is treated with an excess of an organic or inorganic acid, in the case of acid addition salts of a base, or an excess of organic or inorganic base where the molecule contains a COOH for example.

Pharmaceutical compositions of the present invention comprise a pharmaceutical carrier or diluent and some amount of a compound of the formula (I). The compound may be present in an amount to effect a physiological response, or it may be present in a lesser amount such that the user will need to take two or more units of the composition to effect the treatment intended. These compositions may be made up as a solid, liquid or in a gaseous form. Or one of these three forms may be transformed to another at the time of being administered such as when a solid is delivered by aerosol means, or when a liquid is delivered as a spray or aerosol.

The nature of the composition and the pharmaceutical carrier or diluent will, of course, depend upon the intended route of administration, for example parenterally, topically, orally or by inhalation. For topical administration the pharmaceutical composition will be in the form of a cream, ointment, liniment, lotion, pastes, aerosols, and drops suitable for administration to the skin, eye, ear, or nose.

For parenteral administration the pharmaceutical composition will be in the form of a sterile injectable liquid such as an ampule or an aqueous or non-aqueous liquid suspension.

For oral axiministration the pharmaceutical composition will be in the form of a tablet, capsule, powder, pellet, atroche, lozenge, syrup, liquid, or emulsion.

When the pharmaceutical composition is employed in the form of a solution or suspension, examples of appropriate pharmaceutical carriers or diluents include: for aqueous systems, water; for non-aqueous systems, ethanol, glycerin, propylene glycol, corn oil, cottonseed oil, peanut oil, sesame oil, liquid parafins and mixtures thereof with water; for solid systems, lactose, kaolin and mannitol; and for aerosol systems, dichlorodifluoromethane, chlorotrifluoroethane and compressed carbon dioxide. Also, in addition to the pharmaceutical carrier or diluent, the instant compositions may include other ingredients such as stabilizers, antioxidants, preservatives, lubricants, suspending agents, viscosity modifiers and the like, provided that the additional ingredients do not have a detrimental effect on the therapeutic action of the instant compositions. The pharmaceutical preparations thus described are made following the conventional techniques of the pharmaceutical chemist as appropriate to the desired end product.

In these compositions, the amount of carrier or diluent will vary but preferably will be the major proportion of a suspension or solution of the active ingredient. When the diluent is a solid it may be present in lesser, equal or greater amounts than the solid active ingredient.

Usually a compound of formula I is administered to a subject in a composition comprising a nontoxic amount sufficient to produce an inhibition of the symptoms of a disease in which leukotrienes are a factor. Topical formulations will contain between about 0.01 to 5.0% by weight of the active ingredient and will be applied as required as a preventative or curative agent to the affected area. When employed as an oral, or other ingested or injected regimen, the dosage of the composition is selected from the range of from 50 mg to 1000 mg of active ingredient for each adrrύnistration. For convenience, equal doses will be administered 1 to 5 times daily with the daily dosage regimen being selected from about 50 mg to about 5000 mg.

No unacceptable toxicological effects are expected when these compounds are administered in accordance with the present invention. The following examples are given to more fully illustrate the described invention. These examples are intented solely for illustrating the invention and should not be read to limit the invention in any manner. Reference is made to the claims for what is reserved to the inventors hereunder. Methods Of Preparation

Synthetic Scheme(s) With Textual Description

Compounds of Formula (I) may be prepared by the processes disclosed herein. The process comprises reacting a terminal acetylene, wherein Z isdefined in relation to Formula (I), or a group convertible to Z, as, e.g., compound 1 -Scheme 1. with an appropriate halide, R3X, wherein R3 represents R3 as defined in relation to Formula (I) or a group convertible to R3, in the presence of a suitable catalyst. A suitable catalyxt is, for example, copper(I) halide and a bivalent or zero valent palladium compound in the presence of, e.g., triphenylphosphine in a suitable solvent, such as an amine. See for example the procedure of Brandsma et al. (Syn. Comm., 1990, 20, 1889). This provides a compound of the Formula 2-Scheme 1. Compounds of Formula 1 -Scheme 1 may be prepared by procedures analogous to those described in a co-pending U.S. patent application filed on even date herewith and identified as P50284.

Scheme 1

a) Pd(PPh 3)₄, PPh 3, Cul, R ₃X, piperidine

The intermediate compounds represented by Formula 1 -Scheme 1 may be prepared by the following prodecure: a) For those intermediates wherein X and X3 are other than Br, I, NO2, amine, formyl amine, or S(O)m' when m' is 1 or 2, reacting a compound of Formula (A)

wherein Ri represents Ri as defined in relation to Formula (I) or a group convertable to Ri and X represents X as defined in relation to Formula (I) or a group convertable to X and X3 represents X3 as defined in relation to Formula (I) or a group convertable to X3 and X4 is a counter ion (e.g., lithium, magnesium, etc.) with a compound of the Formula (B)

wherein X5 is, e.g., OCH3, OC2H5, OCH(CH3)2, etc., followed by appropriate workup to provide a compound of the Formula (C)

wherein Ri represents Ri as defined in relation to Formula (I) or a group convertable to Ri and X represents X as defined in relation to Formula (I) or a group convertable to X and X3 represents X3 as defined in relation to Formula (I) or a group convertable to X3 (see the patent application WO 9115-451- A published by WIPO). Michael-type reaction of such a compound of the Formula (4) with the appropriate precursor of R3 then provides a compound of the Formula ( 1 ); for example, use of methylaluminum cyanide provides a compound of the Formula (1) wherein Ri represents Ri as defined in relation to Formula (I) or a group convertable to Ri and X represents X as defined in relation to Formula (I) or a group convertable to X and X3 represents X3 as defined in relation to Formula (I) or a group convertable to X3 and the 3- position on the cyclohexyl ring is substituted by CN.

Compounds of Formula (I) wherein R3 is CHO and Z is O may be prepared from the compounds having the CN at the 3- position and Z is O after appropriate protection of the ketone as, e.g., a ketal, followed by reduction of the CN moiety with, e.g., di-isobutylaluminum hydride, followed by appropriate workup and kedif Formula (I) wherein R3 is CH2OH and Z is O may be prepared by reduction of the compound of Formula (I) in which R3 is CHO and =Z is a ketal protecting group with, e.g., sodium borohydride, followed by appropriate workup and ketone deprotection. The acetylene group is obtained by protecting the carbonyl group as a ketal by reacting the ketal with a mixture of dimethyl (diazomethyl)phosphonate and potassium t-butoxide or other suitable base, in an inert solvent, such as tetrahydrofuran, at reduced temperature, followed by appropriate workup and ketone deprotection to provide the compounds of Formula (I) wherein R3 is C__CH. b) Intermediates leading to Formula (I) wherein X or X3 is formyl amine and Z is O may be prepared by formylating, at the last step, a compound wherein =Z is a protected ketone and X is NH2, obtained by removal of a protecting group from the amine functionality; such protective groups are well known to those skilled in the art, See Greene, T. and Wuts, P.G.M., Protecting Groups in Organic Synthesis, 2nd Ed., John Wiley and Sons, New York (1991). c) Intermediates leading to Formula (I) wherein X or X3 is Br or I and Z is O may be prepared from a similarly deprotected amine by diazotization of the amine and diazonium displacement via Sandmeyer reaction. d) Intermediates leading to Formula (I) wherein X or X3 is NO2 and Z is O may be prepared from a similarly deprotected amine by oxidation of the amine to the nitro group. e) Intermediates leading to Formula (I) wherein Y is S(O)_m' when m' is 1 or 2 and Z is O may be prepared from the compounds of Formula (I) wherein Y is S by oxidation of the SR2 moiety under conditions well known to those skilled in the art. To obtain compounds where Z is defined herein above for Formula I, reference is made to the procedures in co-pending U.S. application 08/130215 and PCT application PCT/US94/10815 filed 23 September 1994 where, by analogy, there are illustrated means for making intermediates leading to the present compounds as regards the definition of Z herein. Alternatively, compounds of the Formula (I), wherein Z and R3 represent Zand

R3 as defined in relation to Formula (I) or a group convertible to Z or R3, may be prepared from the corresponding ketones as, e.g., compound 1 -Scheme 2, by the synthetic procedures described above. Scheme 2

Alternatively, oxidative carbonylation of a terminal acetylene as, e.g., compound 1 -Scheme 3. using an appropriate metal salt, such as a copper salt with a catalytic amount of a palladium salt, in the presence of a suitable base as an acid trap, such as sodium acetate, in a suitable alcohol, such as methanol, as in the method of Tsuji et al. (Tet. Lett., 1980, 21, 849), then provides the compound of the Formula 2z Scheme 3: such compounds may then be converted to compounds of the Formula (I) by manipulation of the ketone as described above and by independent manipulation of the carboxylic ester moiety using standard transesterification or amidation conditions.

Scheme 3

COOCH ₃

a) PdCI ₂ , CuCI . NaO ₂ CCH ₃ , CO, CH ₃OH; b) as in Scheme 2

Preparation of the remaining compounds of the Formula (I) may be accomplished by procedures analogous to those described above and in the Examples, infra.

It will be recognized that some compounds of the Formula (I) may exist in distinct diastereomeric forms possessing distinct physical and biological properties; such isomers may be separated by standard chromatographic methods. Examples Example 1 Preparation of 1.4-bis- ( r3-(3-cvclopentyloxy-4-methoxyphenyl)cyclohexan- 1 -onl-3- yl}buta-1.3-diyne la) 3-(3-cyclopentyloxy-4-me oxyphenyl)-3-(trimethylsilylethynyl)cyclohexan- 1 -one n-Butyllithium (2.45 M in hexanes, 5.7 mL, 13.96 mmol) was added dropwise over 5 min to a solution of trimethylsilylacetylene ( 1.97 mL, 13.96 mmol) dissolved in dry ether (30 mL) at -45°C under an argon atmosphere. After 1.5 h, this solution was cannulated into a solution of dimethylaluminum chloride (1.0 M n hexanes, 13.96 mL, 13.96 mmol). After 3.5 h at room temperature, the mixture was filtered through

Celite® under an argon atmosphere. In a separate flask, diisobutylaluminum hydride (1.0 M in toluene, 1.4 mL, 1.4 mmol) was added dropwise to a stirred mixture of nickel acetylacetonate (360 mg, 1.4 mmol) in dry ether (25 mL) at 0°C under an argon atmosphere. After 10 min, the mixture was cooled to -10°C and the solution of the aluminum acetylide was added via cannula over 15 min. A sample of 3-(3- cyclopentyloxy-4-methoxyphenyl)cyclohex-2-en-l-one (2.0 g, 6.98 mmol, prepared by the procedures described in U.S. patent 5362915 ) dissolved in dry ether (70 mL) was added dropwise over 20 min. After 18 h at room temperature, the mixture was poured into a 100 mL saturated aqueous solution of potassium phosphate (monobasic) at 0°C, lOOmL of aqueous 3N HCl solution was added and the aqueous layer was extracted twice with ether. The combined extract was washed with brine, was dried (magnesium sulfate) and was evaporated. Purification by flash chromatography, eluting with 2: 1 hexanes/ether, followed by trituration from ether/hexanes, then furthur purification of the mother liquor by flash chromatography, eluting with 4:1 hexanes/ethyl acetate, followed by trituration from ether/hexanes, provided a white solid, mp 102- 103°C.

1 b) 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-ethynylcyclohexan- 1 -one A mixture of potassium fluoride (900 mg, 15.6 mmol) and 3-(3- cyclopentyloxy-4-memoxyphenyl)-3-(trimethylsilylethynyl)cyclohexan- 1-one (0.3 g, 0.78 mmol) was stirred in dry N.N-dimethylformamide (3 mL) under an argon atmosphere. After 18 h, the solvent was removed in vacuo, the residue was partitioned between water and ethyl acetate, the aqueous layer was extracted twice with ethyl acetate, the combined extract was dried (magnesium sulfate) and was evaporated. Purification by flash chromatography, eluting with 4:1 hexanes/ethyl acetate, provided a clear colorless oil. Anal. (C20H24O3- 1/10 H2O) calcd: C 76.45, H 7.76; found: C 76.32, H 7.60. 1 c) 1 ,4-bis- { [3-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan- 1 -on]-3-yl } buta- 1 ,3- diyne

Copper (II) acetate monohydrate (0.40g, 2.02 mmol) was added to a solution of 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-ethynylcyclohexan- 1 -one (0.30g, 0.96mmol) dissolved in 1 : 1 :4 pyridine methanol/ether (75 mL). The mixture was refluxed under an argon atmosphere. After 30 h, the solvents were evaporated and the residue was partitioned between dichloromethane and aqueous 3N HCl. The aqueous layer was extracted twice with dichloromethane, the combined extract was washed with brine, was dried (magnesium sulfate) and was evaporated. Purification by flash chromatography, eluting with 99: 1 chloroform/methanol, followed by trituration from ether/hexanes, provided a white solid, mp 173-174.5°C.

Example 2 Preparation of 1.4-έ>i -{([3-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-l- yhdinelmalononitrile)-3-yl } buta- 1.3-diyne

A mixture of l,4-_>ι^'j-{[3-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-l- on]-3-yl}buta-l,3-diyne (0.2 g, 0.32 mmol, prepared as per Example 1 and malononitrile (0.042 g, 0.64 mmol) is heated to 110°C. To this melt is added water (2 mL) containing a trace of β-alanine and heating is continued for an additional 3 h. The mixture is cooled, is partitioned between water and ethyl acetate, is extracted twice with ethyl acetate, the organic extract is dried (potassium carbonate) and the solvent is removed in vacuo. Purification by flash chromatography provides the title compound.

Example 3 Preparation of 1.4-_>is-( (methyl r3-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-l- ylidine1acetate)-3-yl }buta- 1.3-diyne A solution of methy diethylphosphonoacetate (1.2 mL, 6.68 mmol) in ethylene glycol dimethyl ether (10 mL) is treated with solid sodium hydride (0.22 g, 7.3 mmol, 80% dispersion in mineral oil) at room temperature under an argon atmosphere. After stirring for 1.5h, a solution of 1 ,4-bis- { [3-(3-cyclopentyloxy-4- methoxyphenyl)cyclohexan-l-on]-3-yl}buta-l,3-diyne (2.08 g, 3.34 mmol) is added and the mixture is allowed to stir for an additional 3 h. The reaction mixture is partitioned between methylene chloride and water, is extracted twice, is dried (potassium carbonate) and is evaporated. Purification by flash column chromatography provides the title compound.

Proceeding in a similar manner, but substituting the appropriate intermediates for those recited above, the other compounds of this invention can be prepared. Utility Examples EXAMPLE A Inhibitory effect of compounds of Formula (I) on in vitro TNF production by human monocytes

The inhibitory effect of compounds of Formula (I) on in vitro TNF production by human monocytes may be determined by the protocol as described in Badger et al,

EPO published Application 0411 754 A2, February 6, 1991, and in Hanna, WO

90/15534, December 27, 1990.

EXAMPLE B

Two models of endotoxic shock have been utilized to determine in vivo TNF activity for the compounds of Formula (I). The protocol used in these models is described in Badger et al, EPO published Application 0411 754 A2, February 6,

1991, and in Hanna, WO 90/15534, December 27, 1990.

The compound of Example 1 herein demonstrated a positive in vivo response in reducing serum levels of TNF induced by the injection of endotoxin.

EXAMPLE C Isolation of PDE Isozymes

The phosphodiesterase inhibitory activity and selectivity of the compounds of

Formula (I) can be determined using a battery of five distinct PDE isozymes. The tissues used as sources of the different isozymes are as follows: 1) PDE lb, porcine aorta; 2) PDE Ic, guinea-pig heart; 3) PDE HI, guinea-pig heart; 4) PDE IV, human monocyte; and 5) PDE V (also called "la"), canine trachealis. PDEs la, lb, Ic and HI are partially purified using standard chromatographic techniques [Torphy and Cieslinski, Mol. Pharmacol., 37:206-214, 1990]. PDE IV is purified to kinetic homogeneity by the sequential use of anion-exchange followed by heparin-Sepharose chromatography [Torphy et al, J. Biol. Chem., 267:1798-1804, 1992].

Phosphodiesterase activity is assayed as described in the protocol of Torphy and Cieslinski, Mol. Pharmacol., 37:206-214, 1990. Positive ICso's in the nanomolar to μM range for compounds of the workings examples described herein for Formula (I) have been demonstrated.

Claims

What is claimed is:

1. A compound of formula (I)

wherein:

R! is -(CR4R5)nC(O)O(CR4R5)mR6, -(CI_4R5)nC(O)NR4(CR4R5)mR6, -(CR4R5)nO(CR4R5)mR6, or -(CR4R5)_rR6 herein the alkyl moieties unsubstituted or substituted with one or more halogens; m is 0 to 2; n is 0 to 4; r is 0 to 6;

R4 and R5 are independently selected hydrogen or C 1 -2 alkyl; R6 is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCi-3 alkyl, halo substituted aιyloxyCi-3 alkyl, indanyl, indenyl, C7-11 polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3-6 cycloalkyl, or a C4-6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocyclic moiety is unsubstituted or substituted by 1 to 3 methyl groups, one ethyl group, or an hydroxyl group; provided that: a) when R6 is hydroxyl, then m is 2; or b) when R6 is hydroxyl, then r is 2 to 6; or c) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then m is 1 or 2; or d) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl,

2-tetr___ydrofuranyl,or 2-tetrahydrothienyl, then r is 1 to 6; e) when n is 1 and m is 0, then R6 is other than H in

-(CR4R5)nO(CR4R5)mR6;

X is YR2» fluorine, NR4R5, or formyl amine; Y is O or S(O)nϊ; m' is O, l, or 2; X2 is O or NRδ; X3 is hydrogen or X; X4 is H, R9, OR8, CN, C(O)R8, C(O)ORδ, C(O)NRgR8, or NRδRδ;

R₂ is independently selected from -CH3 or -CH2CH3 optionally substituted by 1 or more halogens; s is 0 to 4; W is alkyl of 2 to 6 carbons, alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms;

R3 is COOR14, C(O)NR4Ri4 or R7;

Z is C(-CN)2, CR14CN, CRi4C(O)OR8, CRi4C(O)NRgRl4. C(-CN)NO2, C(-CN)C(O)OR9, C(-CN)OC(O)R9, C(-CN)OR9, or C(-CN)C(O)NRδRl4; Y^* is O or S;

R7 is -(CR4R5)qRi2 or C g alkyl wherein the R12 or C g alkyl group is unsubstituted or substituted one or more times by methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -F, -Br, -Cl, -NO2, -NRioRl b -C(O)Rg, -Cθ2Rδ, -O(CH₂)_qRδ, -CN, -C(O)NRιoRι ι, -O(CH₂)_qC(O)NRιoRl l, -O(CH₂)_qC(O)R9, -NRiθC(O)NRιoRl 1, -NRlθC(O)Rι 1, -NRιoC(O)OR9, -NRιoC(O)Ri3, -C(NRiθ)NRιoRl l, -C(NCN)NRιoRl l, -C(NCN)SR9, -NRιoC(NCN)SR9 , -NRiθC(NCN)NRιoRll, -NRlθS(O)2R9, -S(O)_m-R9, -NRiθC(O)C(O)NRκ)Rl l, - NRιoC(O)C(O)Rιo, or R₁₃; q is O, l, or 2; R12 is R 3, C3-C7 cycloalkyl, or an unsubstituted or substituted aryl or heteroaryl group selected from the group consisting of (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, (1- or 2-imidazolyl), pyrrolyl, piperazinyl, piperidinyl, morpholinyl, furanyl, (2- or 3-thienyl), quinolinyl, naphthyl, and phenyl;

Rg is independently selected from hydrogen or R9; R9 is C 1 _4 alkyl optionally substituted by one to three fluorines;

RlO is ORg or Rn;

R is hydrogen, or C .4 alkyl unsubstituted or substituted by one to three fluorines; or when Rio and Ri 1 are as NRioRl 1 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and one or more additional heteroatoms selected from O, N, or S;

R 13 is a substituted or unsubstituted heteroaryl group selected from the group consisting of oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, and thiadiazolyl, and where R|₃ is substituted on Rι₂ or R₁ the rings are connected through a carbon atom and each second Rι₃ ring may be unsubstituted or substituted by one or two C _2 alkyl groups unsubstituted or substituted on the methyl with 1 to 3 fluoro atoms; Rl4 is hydrogen or R7; or when Rg and R14 are as NR8R14 they may together with the nitrogen form a 5 to 7 membered ring comprised of carbon or carbon and one or more additional heteroatoms selected from O, N, or S; provided that: (f) R7 is not Cι_4 alkyl unsubstituted or substituted by one to three fluorines; or the pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 wherein R is -CH2-cyclopropyl, -CH2-C5-6 cycloalkyl, -C4-6 cycloalkyl unsubstituted or substituted by OH, te_rahyc_rof__ran-3-yl, (3- or 4-cyclopentenyl), benzyl or -Ci-2 alkyl unsubstituted or substituted by 1 or more fluorines, and -(CH2)2-4 OH; R2 is methyl or fluoro- substituted alkyl, W is ethynyl or 1,3-butadiynyl; R₃ is R₇ where R₇ is an unsubstituted or substituted aryl or heteroaryl ring, X is YR2, and Z is CRi4C(O)OR8-

3. A compound according to claim 2 wherein Ri is -CH2-cyclopropyl, cyclopentyl, 3-hydroxycyclopentyl, methyl or CF₂H; X is YR2; Y is oxygen; X2 is oxygen; X3 is hydrogen; and R2 is CF2H or methyl, W is ethynyl or 1,3-butadiynyl, and R3 is a substituted or unsubstituted pyrimidinyl ring.

4. A compound according to claim 1 which is

1 ,4-bis- { [3-(3 -cyclopentyloxy-4-methoxyphenyl)cyclohexan- 1 -on] -3-yl } buta- 1,3-diyne, 1 ,4-bis-{ ([3-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan- 1 - y_idine]malononit_ile)-3-yl Jbuta- 1 ,3-diyne, and

1 ,4-bis- { (methyl [3-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan- 1 - ylidine]acetate)-3-yl}buta-l,3-diyne.

5. A pharmaceutical preparation comprising a compound of claims 1 in admixture with a pharmaceutically acceptable excipient.